fampridine

NICE Still Opposes Adding Fampyra to NHS for England

The National Institute for Health and Care Excellence (NICE) in England is set to again recommend against adding Fampyra (fampridine) to the list of medications available to multiple sclerosis (MS) patients with walking difficulties through the countryā€™s national health service (NHS). The poor cost-effectiveness of Fampyra ā€” sold…

Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland

After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines ConsortiumĀ (SMC) for use in the country’sĀ National Health System (NHS) to treat walking disabilities in adults withĀ multiple sclerosis (MS). Scotland…

Ampyra Aided Walking in PPMS and RMS Patients Over Long Term, Neurologist Says in Interview

AmpyraĀ (dalfampridine) shows long-term efficacy in improving walking ability in peopleĀ with multiple sclerosis, according to a study evaluating the treatment’s use in progressive and relapsing MS patients over two years. The study, ā€œMonitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis,ā€ was published in the…

Transcript of Interview on Ampyra Research, MS Walking Ability and Long-Term Use

Multiple Sclerosis News Today interviewedĀ Dr. Linard Filli,ā€Ø an MS researcher at the University Hospital ZurichĀ involved in clinical studies of prolonged release Ampyra (dalfampridine), on walking ability in MS patients,Ā and Dr. Andrew Blight, chief scientific officer at Acorda Therapeutics, the treatment’s developer. Here is a full transcript of that interview.Ā An…

#ECTRIMS2016 – MS Patients Achieve Sustained Improvements in Mobility with Ampyra

A recent study showed that the clinical benefits offered by Ampyra (fampridine) in improving mobility among multiple sclerosis (MS) patients hasĀ clinical significance. The results were shown in an oral presentation, ā€œSustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study,ā€ atĀ the European Committee for…